Using Low Intensity Focused Ultrasound to Modulate Deep Brain Areas for Tremor Control in Parkinson's Disease Patients.

NCT ID: NCT06259708

Last Updated: 2025-03-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-01

Study Completion Date

2025-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Researchers have found that a treatment called Magnetic Resonance guided Focused Ultrasound (MRgFUS) can effectively reduce tremors in patients with essential tremor (ET) and Parkinson's disease (PD). They noticed that ET patients initially responded better to the treatment than PD patients, but by the end of the treatment, both groups showed similar improvement. The study also suggested that targeting a specific area of the brain called the Zona Incerta (ZI) may be more beneficial for PD patients. Based on these findings, the investigators plan to use low-intensity focused ultrasound to directly modulate the ZI area and investigate the mechanisms of reduced tremors in PD patients. The investigators will also compare the effectiveness of this approach with the current target, the ventral intermediate nucleus (Vim) of the thalamus. The investigators will use a simulation model to determine the best ultrasound parameters for this new approach and will also examine the impact of the treatment on the brain's network activity using functional Magnetic Resonance Imaging. Success of this project may lay the foundation for finding a more effective target for MRgFUS treatment of PD tremor.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

The investigators will use a crossover design for this study as it requires fewer participants and removes variance between participants in the outcomes that are irrelevant to the stimulation type in comparison to other designs where each participant only receives one stimulation. All participants receive all the stimulation types (Vim-LIFU and ZI-LIFU), but the order in which they get the stimulation types is randomized.
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vim first

Participants assigned to this arm get LIFU stimulation in the Vim before the ZI.

Group Type EXPERIMENTAL

Low intensity focused ultrasound

Intervention Type DEVICE

Sonication with low intensity focused ultrasound in two deep brain structures (ZI and Vim).

ZI first

Participants assigned to this arm get LIFU stimulation in the Vim before the ZI.

Group Type EXPERIMENTAL

Low intensity focused ultrasound

Intervention Type DEVICE

Sonication with low intensity focused ultrasound in two deep brain structures (ZI and Vim).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low intensity focused ultrasound

Sonication with low intensity focused ultrasound in two deep brain structures (ZI and Vim).

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed diagnosis of Parkinson's disease
* Resting tremor score (MDS-UPDRS III 3.17 Rest Tremore Amplitude (RUE or LUE)) ≥ 2
* Between the ages of 40-80 years
* Hoehn and Yahr stage between 1-3 (mild to moderate PD) in the "ON" state
* Patients who are willing to have a partial (\~8 cm diameter circular area above the ear) hair shaving.

Exclusion Criteria

* Atypical Parkinsonism
* History of essential tremor
* Dementia preventing informed consent
* Change in Parkinson's medication with the last 2 weeks
* Neurological disease other than PD, including Alzheimer's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, a brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma
* Unstable medical conditions or serious disease/conditions (e.g., cancer undergoing active treatment, poorly controlled diabetes)
* Concurrent treatment for PD with Duodopa
* Concurrent treatment for PD with deep brain stimulation (DBS)
* Thickness of the temporal bone \< 7 mm
* Individuals should also not participate if they have any of the following contraindications for undergoing fMRI scanning:
* Cardiac pacemaker, wires, or defibrillator
* Metal in eye or orbit, including the history of any eye injury involving metal fragments and increased risk due to (history of) working as a metal worker (grinding, machining, or welding)
* Ferromagnetic aneurysm clip
* Possibility of pregnancy
* Artificial heart valve
* Ear or eye implant, including cochlear implant
* Brain aneurysm clip
* Implanted drug infusion pump
* Electrical stimulator to nerves or bones
* Coil, catheter, or filter in any blood vessel
* Orthopedic hardware (artificial joint, plate, screw, rod)
* Other metallic prostheses
* Shrapnel, bullets, or other metal fragments
* Surgery, piercings or tattoos (including tattooed eyeliner) in the last six weeks
* Medication releasing skin patches (i.e. nicotine, birth control, nitroglycerine)
* History of claustrophobia
Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Focused Ultrasound Foundation

OTHER

Sponsor Role collaborator

University of British Columbia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Martin McKeown

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hongchae Baek, PhD

Role: PRINCIPAL_INVESTIGATOR

Food and Drugs Administration

Soojin Lee, PhD

Role: PRINCIPAL_INVESTIGATOR

University of British Columbia

Martin J. McKeown, MD, FRCPC

Role: PRINCIPAL_INVESTIGATOR

University of British Columbia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of British Columbia, DMCBH

Vancouver, British Columbia, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H23-00480

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

VIM+PTT MRgFUS for PD
NCT07044973 RECRUITING NA
TUS to Disrupt Pathological Oscillations
NCT06932185 ENROLLING_BY_INVITATION NA